Diacylglycerol o-acyltransferase 2alpha (DGAT2alpha)
OwnerSylvaine Cases, Robert V. Farese +2inventors
InventorsSylvaine Cases, Robert V. Farese, Scot Stone, Ping Zhou
Life of this patent
Estimating the term…
Abstract
Nucleic acid compositions encoding mammalian DGAT2α polypeptide products with diglyceride acyltransferase activity, as well as the mammalian DGAT2α polypeptide products encoded thereby and methods for producing the same, are provided. The subject DGAT2α polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies and in the production of triacylglycerols.
Claims23
A mammalian polynucleotide present in other than its natural environment encoding a DGAT2α product.
The polynucleotide according to claim 2, wherein said polynucleotide comprises a sequence substantially similar or identical to a sequence selected from the group consisting of SEQ ID NO:01 and SEQ ID NO:
- 03.
A mammalian DGAT2α polypeptide present in other than its naturally occurring environment.
Substantially pure mammalian DGAT2α
Isolated mammalian DGAT2α.
A monoclonal antibody binding specifically to a DGAT2α polypeptide.
A method for inhibiting the activity of a DGAT2α protein, said method comprising:
- contacting said DGAT2α protein with an agent that inhibits the activity of said DGAT2α protein.
A method of modulating a symptom in a mammalian host of a disease condition associated with DGAT2α activity, said method comprising:
- administering to said host a pharmaceutical composition comprising an effective amount of an active agent that modulates said DGAT2α activity in said host.
A method of producing a triacylglycerol, said method comprising:
- contacting a diacylglyercol and fatty acyl CoA with a DGAT2α polypeptide under conditions sufficient to said triacylglycerol to be produced.
Dependencies are inferred from the claim text.